Actively Recruiting
Global Phase III Study of Volrustomig Versus Placebo in Women With High-Risk Locally Advanced Cervical Cancer After Platinum-Based Chemoradiation
Led by AstraZeneca · Updated on 2026-09-30
800
Participants Needed
205
Research Sites
148 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial evaluates the safety and effectiveness of Volrustomig in women with high-risk locally advanced cervical cancer FIGO 2018 stage IIIA to IVA who have not shown disease progression after platinum-based concurrent chemoradiation therapy CCRT. It is a global, randomized, double-blind, placebo-controlled Phase III study designed to assess outcomes in this specific patient population. Participants are randomly assigned in equal numbers to receive either Volrustomig or a placebo via intravenous infusion. The study compares these two groups to explore the potential benefits and risks of Volrustomig as a treatment following CCRT in women with high-risk locally advanced cervical cancer. Women taking part in the study will undergo multiple assessments over up to approximately seven years. Researchers monitor progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, subsequent therapies, and safety. Additional evaluations include tumor progression, pharmacokinetics, immunogenicity, adverse events, and patient-reported symptoms and quality of life. Participants provide tumor samples and undergo regular health evaluations during this period.
CONDITIONS
Brief Title
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here